Patients received treatment with anti-IL-4RA or anti-IL-13 (anti-Th2), anti-IL23 or anti-IL-17A (Anti-Th17), or JAK1 inhibitors (with the ability to target Th1) based on their diagnosis of AD, psoriasis, or LP established by clinical and histopathology criteria. Here, IL17A is linked to psoriasis.